Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Demarest

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Protein Engineering, Design & Selection : PEDS|May 12, 2010
Stability engineering of scFvs for the development of bispecific and multivalent antibodiesBrian R Miller, Stephen J Demarest, Alexey Lugovskoy, et al.
Molecular Cancer Therapeutics|August 19, 2010
Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor responseJianying Dong, Stephen J Demarest, Arlene Sereno, et al.
Structure (London, England : 1993)|March 22, 2016
Computationally Designed Bispecific Antibodies using Negative State RepertoiresAndrew Leaver-Fay, Karen J Froning, Shane Atwell, et al.
Protein Science : a Publication of the Protein Society|July 21, 2017
Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodiesK J Froning, A Leaver-Fay, X Wu, et al.
Mabs|March 17, 2015
Fab-based bispecific antibody formats with robust biophysical properties and biological activityXiufeng Wu, Arlene J Sereno, Flora Huang, et al.
Biochemistry|April 11, 2013
Evaluation of Tyro3 expression, Gas6-mediated Akt phosphorylation, and the impact of anti-Tyro3 antibodies in melanoma cell linesStephen J Demarest, Jennifer Gardner, Michelle C Vendel, et al.
Mabs|January 12, 2010
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaRJennifer S Michaelson, Stephen J Demarest, Brian Miller, et al.
Nature Communications|May 13, 2020
Computational stabilization of T cell receptors allows pairing with antibodies to form bispecificsKaren Froning, Jack Maguire, Arlene Sereno, et al.
Nature Communications|May 1, 2025
Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical studyAnja Koester, Derrick R Witcher, Mark Lee, et al.
Nature Biotechnology|January 28, 2014
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interfaceSteven M Lewis, Xiufeng Wu, Anna Pustilnik, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Protein Engineering, Design & Selection : PEDS|May 12, 2010
Stability engineering of scFvs for the development of bispecific and multivalent antibodiesBrian R Miller, Stephen J Demarest, Alexey Lugovskoy, et al.
Molecular Cancer Therapeutics|August 19, 2010
Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor responseJianying Dong, Stephen J Demarest, Arlene Sereno, et al.
Structure (London, England : 1993)|March 22, 2016
Computationally Designed Bispecific Antibodies using Negative State RepertoiresAndrew Leaver-Fay, Karen J Froning, Shane Atwell, et al.
Protein Science : a Publication of the Protein Society|July 21, 2017
Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodiesK J Froning, A Leaver-Fay, X Wu, et al.
Mabs|March 17, 2015
Fab-based bispecific antibody formats with robust biophysical properties and biological activityXiufeng Wu, Arlene J Sereno, Flora Huang, et al.
Biochemistry|April 11, 2013
Evaluation of Tyro3 expression, Gas6-mediated Akt phosphorylation, and the impact of anti-Tyro3 antibodies in melanoma cell linesStephen J Demarest, Jennifer Gardner, Michelle C Vendel, et al.
Mabs|January 12, 2010
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaRJennifer S Michaelson, Stephen J Demarest, Brian Miller, et al.
Nature Communications|May 13, 2020
Computational stabilization of T cell receptors allows pairing with antibodies to form bispecificsKaren Froning, Jack Maguire, Arlene Sereno, et al.
Nature Communications|May 1, 2025
Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical studyAnja Koester, Derrick R Witcher, Mark Lee, et al.
Nature Biotechnology|January 28, 2014
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interfaceSteven M Lewis, Xiufeng Wu, Anna Pustilnik, et al.
Pageof 7